One-Year Follow-Up Completed in PIONEER-III Trial of Sinomed’s Buma Supreme DES
July 13, 2020—Sino Medical Science Technology Inc. (Sinomed), a Tianjin, China–based developer of neuro- and cardiovascular technologies, announced the completion of 1-year follow-up in the randomized global PIONEER-III trial evaluating the Buma Supreme coronary drug-eluting stent (DES).
CE Mark Approved for 1-Month DAPT Indication for High Bleeding Risk Patients Treated With Medtronic’s Resolute Onyx DES
June 5, 2020—Medtronic announced it has received European CE Mark approval for a 1-month dual antiplatelet therapy (DAPT) indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx drug-eluting stent (DES).
Analysis of LEADERS FREE Supports Similar PCI Treatment in Women as in Men With High Bleeding Risk
May 29, 2020—The American College of Cardiology announced a recently published study that demonstrated that women with high bleeding risk should not be denied the benefits of percutaneous coronary intervention (PCI) when indicated and that bleeding avoidance strategies should be uniformly adopted for all patients, especially in women.
MedAlliance Gains CE Mark Approval for Coronary Selution SLR Sirolimus-Eluting Balloon
May 14, 2020—MedAlliance SA announced European CE Mark approval for the Selution SLR 014, a sirolimus drug-eluting balloon (DEB) with sustained limus-release (SLR) for the percutaneous transluminal coronary angioplasty to treat of coronary artery disease.
TWILIGHT Substudy Compares Safety of Bioabsorbable Polymer and Durable Polymer DES in High-Risk Patients Undergoing PCI
May 14, 2020—The Society for Cardiovascular Angiography and Interventions (SCAI) announced that subgroup findings from the TWILIGHT trial sought to reveal whether drug-eluting stents (DESs) coated with a bioabsorbable polymer (BP) provided a safety advantage without compromising efficacy compared with durable polymer (DP) formulations.
Pooled Analysis Shows Substantial Long-Term MACE Risk After PCI for Stable Ischemic Heart Disease
April 13, 2020—In Circulation: Cardiovascular Interventions, Mahesh V. Madhavan, MD, et al published findings from an individual patient-level pooled analysis of 19 randomized coronary stent trials evaluating long-term outcomes after revascularization for stable ischemic heart disease.
PRECOMBAT Compares Stenting and CABG Events at 10 Years
March 30, 2020—The American College of Cardiology (ACC) announced that a study with the longest follow-up to date of patients with a high-risk of left main coronary artery disease (LMCAD) showed no significant differences in rates of death, heart attack, or stroke between patients who were treated with a stent and those who underwent coronary artery bypass graft (CABG) surgery.
Medtronic Reports Results From Onyx ONE Clear Study of 1-Month DAPT in High Bleeding-Risk DES Patients
March 30, 2020—Medtronic announced positive results of the Onyx ONE Clear study that evaluated the company's Resolute Onyx drug-eluting stent (DES) in high bleeding-risk (HBR) patients with 1-month dual antiplatelet therapy (DAPT).
Study Shows Similar 1-Year Outcomes for Women and Men Treated With OrbusNeich's Combo DES
March 21, 2020—Online in Catheterization and Cardiovascular Interventions, Jaya Chandrasekhar, MBBS, et al published findings from an examination of sex differences in 1‐year outcomes with the Combo drug-eluting stent (OrbusNeich).
Meta-Analysis Compares DES and CABG for Left Main Coronary Artery Disease
March 2, 2020—Findings from a meta-analysis comparing percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) versus coronary artery bypass grafting (CABG) for patients with left main coronary artery disease (LMCAD) were published by Yousif Ahmad, MD, et al online ahead of print in European Heart Journal (EHJ).
EACTS Seeks to Collaborate With EXCEL Investigators to Resolve Trial Data Concerns
January 7, 2020—The European Association for Cardio-Thoracic Surgery (EACTS) announced that its Secretary General, Professor Domenico Pagano, MD, on behalf of the EACTS Council, has written to the principal investigators of the EXCEL trial to offer assistance to resolve concerns that have been raised about the trial.
EXCEL Investigators Issue Detailed Response to BBC and EACTS Claims on Trial Conduct and Data Interpretation
December 12, 2019—Gregg W. Stone, MD, et al on behalf of the EXCEL leadership issued a response to the recent news reports and society statements questioning the conduct and data of the EXCEL trial.
EACTS Withdraws Support of Left Main Chapter of European Guidelines for Myocardial Revascularization After BBC Investigation of the EXCEL Trial
December 9, 2019—Professor Domenico Pagano, MD, Secretary General of the European Association for Cardiothoracic Surgery (EACTS), issued a statement in response to the report of the United Kingdom’s BBC Newsnight investigation on the EXCEL trial and the society’s subsequent withdrawal of support for the current guidelines related to myocardial revascularization for left main coronary artery disease (LMCAD) that were established jointly by EACTS and the European Society of Cardiology (ESC).
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in Europe.